| abstract |
The invention relates to compounds of formula (II), where the cycle A 'and the cycle B', each independently mean an optionally substituted 5-6-membered monocyclic aryl or heteroaryl, selected from those indicated in the claims. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants suitable for the treatment of glioblastoma and acute myelogenous leukemia characterized by the presence of mutant IDH2. The present invention also relates to pharmaceutical compositions containing compounds of formula (II) and a pharmaceutically acceptable carrier, and methods of treating these diseases. |